Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-03-29 4:15 pm Purchase | 2024-03-19 | 13G | PASSAGE BIO INC PASG | Lynx1 Capital Management LP | 242,294 8.700% | 223,336 (+1178.06%) | Filing History |
| 2024-02-16 4:57 pm Purchase | 2024-02-06 | 13G | GH RESH PLC SHS GHRS | Lynx1 Capital Management LP | 2,994,059 5.800% | 2,994,059 (New Position) | Filing History |
| 2024-02-14 09:22 am Purchase | 2023-12-31 | 13G | ALPINE IMMUNE SCIENCES INC ALPN | Lynx1 Capital Management LP | 3,813,926 6.600% | 687,753 (+22.00%) | Filing History |
| 2024-02-14 09:21 am Sale | 2023-12-31 | 13G | KINNATE BIOPHARMA INC KNTE | Lynx1 Capital Management LP | 1,997,006 4.200% | -216,172 (-9.77%) | Filing History |
| 2024-02-14 09:21 am Sale | 2023-12-31 | 13G | PASSAGE BIO INC PASG | Lynx1 Capital Management LP | 18,958 0.700% | -148,838 (-88.70%) | Filing History |
| 2024-02-14 09:21 am Purchase | 2023-12-31 | 13G | C4 THERAPEUTICS INC CCCC | Lynx1 Capital Management LP | 3,134,396 6.400% | 12,177 (+0.39%) | Filing History |
| 2024-02-14 09:20 am Purchase | 2023-12-31 | 13G | STOKE THERAPEUTICS INC STOK | Lynx1 Capital Management LP | 2,956,918 6.600% | 292,760 (+10.99%) | Filing History |
| 2024-02-14 09:20 am Sale | 2023-12-31 | 13G | CABALETTA BIO INC CABA | Lynx1 Capital Management LP | 2,139,644 4.990% | -686,332 (-24.29%) | Filing History |
| 2024-02-14 09:19 am Purchase | 2023-12-31 | 13G | PIERIS PHARMACEUTICALS INC PIRS | Lynx1 Capital Management LP | 122,198 9.900% | 51,841 (+73.68%) | Filing History |
| 2024-02-14 09:19 am Sale | 2023-12-31 | 13G | NEOLEUKIN THERAPEUTICS INC NLTX | Lynx1 Capital Management LP | 46 0.100% | -114,511 (-99.96%) | Filing History |
| 2024-02-14 09:18 am Sale | 2023-12-31 | 13G | BIONOMICS LTD ADS BNOX | Lynx1 Capital Management LP | 12,364,575 7.800% | -533,400 (-4.14%) | Filing History |
| 2023-11-13 4:55 pm Purchase | 2023-11-01 | 13G | C4 THERAPEUTICS INC CCCC | Lynx1 Capital Management LP | 3,122,219 6.300% | 3,122,219 (New Position) | Filing History |
| 2023-11-06 4:55 pm Purchase | 2023-10-26 | 13G | STOKE THERAPEUTICS INC STOK | Lynx1 Capital Management LP | 2,664,158 6.000% | 2,664,158 (New Position) | Filing History |
| 2023-10-30 4:21 pm Purchase | 2023-09-29 | 13G | BIONOMICS LTD ADS BNOX | Lynx1 Capital Management LP | 12,897,975 8.200% | 12,897,975 (New Position) | Filing History |
| 2023-06-02 4:56 pm Purchase | 2023-05-31 | 13G | TSCAN THERAPEUTICS INC TCRX | Lynx1 Capital Management LP | 5,224,600 12.200% | 5,224,600 (New Position) | Filing History |
| 2023-02-14 4:07 pm Purchase | 2022-12-31 | 13G | CABALETTA BIO INC CABA | Lynx1 Capital Management LP | 2,825,976 9.700% | 465,664 (+19.73%) | Filing History |
| 2023-02-14 4:06 pm Purchase | 2022-12-31 | 13G | PASSAGE BIO INC PASG | Lynx1 Capital Management LP | 167,796 6.200% | 30,175 (+21.93%) | Filing History |
| 2023-02-14 4:06 pm Purchase | 2022-12-31 | 13G | PIERIS PHARMACEUTICALS INC PIRS | Lynx1 Capital Management LP | 70,357 7.600% | 22,549 (+47.17%) | Filing History |
| 2023-02-14 4:05 pm Purchase | 2022-12-31 | 13G | ALPINE IMMUNE SCIENCES INC ALPN | Lynx1 Capital Management LP | 3,126,173 6.800% | 1,588,828 (+103.35%) | Filing History |
| 2023-01-23 4:28 pm Purchase | 2023-01-13 | 13G | KINNATE BIOPHARMA INC KNTE | Lynx1 Capital Management LP | 2,213,178 5.000% | 2,213,178 (New Position) | Filing History |